The FDA is planning to announce permanent senior center heads alongside the appointment of a new commissioner, including leadership for CBER and CDER, according to three sources familiar with the planning. The personnel slate is expected to be part of broader organizational announcements tied to the transition. The move matters for biotech because center leadership can influence review priorities, oversight posture, and downstream guidance that affects biologics and drug development timelines. It also comes as regulatory transparency and policy execution are under public scrutiny, with ongoing industry interest in how FDA decisions are communicated. Companies are likely to monitor the announcement closely as they plan submissions and trial endpoints ahead of changing leadership direction.